PSNL
Personalis, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$15.88
+1.47%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$15.87
From 52W high−13.60%
Volume3.13M
Market cap$1.70B
P/E (TTM)—
P/S (TTM)24.3x
Div yield—
Key dataOct 19, 2026
Open
$15.87
From 52W high
−13.60%
Volume
3.13M
Market cap
$1.70B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−15.6x
P/E (TTM)
—
RSI (14)
45.7
MomentumView details →
1D Return
+1.47%
YTD Return
+98.93%
SummaryUpdated Jun 1, 2026
Personalis, Inc. (NASDAQ:PSNL) is a cancer genomics company founded in 2011 and headquartered in Menlo Park, California. The company went public in June 2019 and specializes in providing advanced genomic sequencing and data analysis services to support cancer therapy development and large-scale genetic research programs. Personalis has evolved from a broad genomics services provider to focus primarily on minimal residual disease (MRD) testing, a rapidly growing field in cancer diagnostics that helps detect microscopic amounts of cancer remaining after treatment.
Similar companies
Latest newsMore news →
Personalis reported a Q2 2026 net loss of $0.30 per share, missing the Zacks Consensus Estimate of a $0.25 loss and wider than the $0.23 loss a year earlier.76d agoWohl & Fruchter LLP announced an investigation into the fairness of the proposed acquisition of Personalis, Inc. by Tempus AI, Inc. for $16.25 per share.76d agoTEMPUS AI will acquire PERSONALIS at $16.25 per share, with the transaction expected to close between late 2026 and early 2027.92d ago